Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2008

01-12-2008 | NON-THEMATIC REVIEW

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host

Authors: Osvaldo L. Podhajcer, Lorena Gabriela Benedetti, Maria Romina Girotti, Federico Prada, Edgardo Salvatierra, Andrea S. Llera

Published in: Cancer and Metastasis Reviews | Issue 4/2008

Login to get access

Abstract

Tumor growth is essentially the result of an evolving cross-talk between malignant and surrounding stromal cells (fibroblasts, endothelial cells and inflammatory cells). This heterogeneous mass of extracellular matrix and intermingled cells interact through cell–cell and cell–matrix contacts. Malignant cells also secrete soluble proteins that reach neighbor stromal cells, forcing them to provide the soil on which they will grow and metastasize. Different studies including expression array analysis identified the matricellular protein SPARC as a marker of poor prognosis in different cancer types. Further evidence demonstrated that high SPARC levels are often associated with the most aggressive and highly metastatic tumors. Here we describe the most recent evidence that links SPARC with human cancer progression, the controversy regarding its role in certain human cancers and the physiological processes in which SPARC is involved: epithelial–mesenchymal transition, immune surveillance and angiogenesis. Its relevance as a potential target in cancer therapy is also discussed.
Literature
1.
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.PubMed
2.
Liotta, L. A., & Kohn, E. C. (2001). The microenvironment of the tumour–host interface. Nature, 411, 375–379.PubMed
3.
Murphy-Ullrich, J. E. (2001). The de-adhesion activity of matricellular proteins: Is intermediate cell adhesion an adaptive state? Journal of Clinical Investigation, 107(7), 785–790.PubMed
4.
Bornstein, P. (2002). Cell–matrix interactions: The view from the outside. Methods in Cell Biology, 69, 7–11.PubMed
5.
Sage, E. H. (2001). Regulation of interactions between cells and extracellular matrix: A command performance on several stages. Journal of Clinical Investigation, 107(7), 781–783.PubMed
6.
Rosenblatt, S., Bassuk, J. A., Alpers, C. E., Sage, E. H., Timpl, R., & Preissner, K. T. (1997). Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: Characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochemical Journal, 324, 311–319.PubMed
7.
Xie, R. L., & Long, G. L. (1995). Role of N-linked glycosylation in human osteonectin. Effect of carbohydrate removal by N-glycanase and site-directed mutagenesis on structure and binding of type V collagen. Journal of Biological Chemistry, 270(39), 23212–23217.PubMed
8.
Maurer, P., Hohenadl, C., Hohenester, E., Gohring, W., Timpl, R., & Engel, J. (1995). The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domains that binds calcium and collagen IV. Journal of Molecular Biology, 253(2), 347–357.PubMed
9.
Raines, E. W., Lane, T. F., Iruela-Arispe, M. L., Ross, R., & Sage, E. H. (1992). The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and BB and inhibits the binding of PDGF to its receptors. Proceedings of the National Academy of Sciences of the United States of America, 89, 1281–1285.PubMed
10.
Hasselaar, P., & Sage, E. H. (1992). SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. Journal of Cellular Biochemistry, 49, 272–283.PubMed
11.
Tremble, P. M., Lane, T. F., Sage, E. H., & Werb, Z. (1993). SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. Journal of Cell Biology, 121(6), 1433–1444.PubMed
12.
Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C., Bover, L., Chernajovsky, Y., et al. (1997). Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nature Medicine, 3(2), 171–175.PubMed
13.
Lane, T. F., Iruela-Arispe, M. L., & Sage, E. H. (1992). Regulation of gene expression by SPARC during angiogenesis in vitro, changes in fibronectin, thrombospondin-1 and plasminogen activator inhibitor-1. Journal of Biological Chemistry, 267(23), 16736–16745.PubMed
14.
Gilles, C., Bassuk, J. A., Pulyaeva, H., Sage, E. H., Foidart, J.-M., & Thompson, E. W. (1998). SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Research, 58(23), 5529–5536.PubMed
15.
Murphy-Ullrich, J. E., Lane, T. F., Pallero, M. A., & Sage, E. H. (1995). SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca2+ binding EF-hand. Journal of Cellular Biochemistry, 57, 341–350.PubMed
16.
Brekken, R. A., & Sage, E. H. (2000). SPARC, a matricellular protein: At the crossroads of cell–matrix. Matrix Biology, 19(7), 569–580.PubMed
17.
Bradshaw, A. D., Francki, A., Motamed, K., Howe, C., & Sage, E. H. (1999). Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Molecular Biology of the Cell, 10(5), 1569–1579.PubMed
18.
Ledda, M. F., Bravo, A. I., Adris, S., Bover, L., Mordoh, J., & Podhajcer, O. L. (1997). The expression on the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. Journal of Investigative Dermatology, 108(2), 210–214.PubMed
19.
Rumpler, G., Becker, B., Hafner, C., McClelland, M., Stolz, W., Landthaler, M., et al. (2003). Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Experimental Dermatology, 12(6), 761–771.PubMed
20.
Massi, D., Franchi, A., Borgognoni, L., Reali, U. M., & Santucci, M. (1999). Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Human Pathology, 30(3), 339–344.PubMed
21.
Ikuta, Y., Nakatsura, T., Kageshita, T., Fukushima, S., Ito, S., Wakamatsu, K., et al. (2005). Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clinical Cancer Research, 11(22), 8079–8088.PubMed
22.
Sosa, M. S., Girotti, M. R., Salvatierra, E., Prada, F., de Olmo, J. A., Gallango, S. J., et al. (2007). Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics, 7(22), 4123–4134.PubMed
23.
Smit, D. J., Gardiner, B. B., & Sturm, R. A. (2007). Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. International Journal of Cancer, 121(12), 2653–2660.
24.
Porter, P. L., Sage, E. H., Lane, T. F., Funk, S. E., & Gown, A. M. (1995). Distribution of SPARC in normal and neoplastic human tissue. Journal of Histochemistry and Cytochemistry, 43(8), 791–800.PubMed
25.
Bellahcene, A., & Castronovo, V. (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. American Journal of Pathology, 146(1), 95–100.PubMed
26.
Podhajcer, O. L., Wolf, C., Lefebvre, O., Segain, J. P., Rouyer, N., Stoll, I., et al. (1996). Comparative expression of the SPARC and stromelysin-3 genes in mammary tumors. The Breast, 5, 13–20.
27.
Jones, C., Mackay, A., Grigoriadis, A., Cossu, A., Reis-Filho, J. S., Fulford, L., et al. (2004). Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer. Cancer Research, 64(9), 3037–3045.PubMed
28.
Lien, H. C., Hsiao, Y. H., Lin, Y. S., Yao, Y. T., Juan, H. F., Kuo, W. H., et al. (2007). Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: Identification of genes potentially related to epithelial–mesenchymal transition. Oncogene, 26(57), 7859–7871.PubMed
29.
Barth, P. J., Moll, R., & Ramaswamy, A. (2005). Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Archiv, 446(5), 532–536.PubMed
30.
Parker, B. S., Argani, P., Cook, B. P., Liangfeng, H., Chartrand, S. D., Zhang, M., et al. (2004). Alterations in vascular gene expression in invasive breast carcinoma. Cancer Research, 64(21), 7857–7866.PubMed
31.
Iacobuzio-Donahue, C. A., Argani, P., Hempen, P. M., Jones, J., & Kern, S. E. (2002). The desmoplastic response to infiltrating breast carcinoma: Gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Research, 62(18), 5351–5357.PubMed
32.
Graham, J. D., Balleine, R. L., Milliken, J. S., Bilous, A. M., & Clarke, C. L. (1997). Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. European Journal of Cancer, 33(10), 1654–1660.PubMed
33.
Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., et al. (2005). Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clinical Cancer Research, 11(14), 5175–5180.PubMed
34.
Watkins, G., Douglas-Jones, A., Bryce, R., Mansel, R. E., & Jiang, W. G. (2005). Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins, Leukotrienes and Essential Fatty Acids, 72(4), 267–272.
35.
Rempel, S. A., Golembieski, W. A., Ge, S., Lemke, N., Elisevich, K., Mikkelsen, T., et al. (1998). SPARC: A signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. Journal of Neuropathology and Experimental Neurology, 57(12), 1112–1121.PubMed
36.
Golembieski, W. A., Ge, S., Nelson, K., Mikkelsen, T., & Rempel, S. A. (1999). Increased SPARC expression promotes U87 glioblastoma invasion in vitro. International Journal of Developmental Neuroscience, 17(5–6), 463–472.PubMed
37.
Rich, J. N., Shi, Q., Hjelmeland, M., Cummings, T. J., Kuan, C. T., Bigner, D. D., et al. (2003). Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. Journal of Biological Chemistry, 278(18), 15951–15957.PubMed
38.
Schultz, C., Lemke, N., Ge, S., Golembieski, W. A., & Rempel, S. A. (2002). Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Research, 62, 6270–6277.PubMed
39.
Vajkoczy, P., Manger, M. D., Goldbrunner, R., Ge, S., Fong, T. A., Vollmar, B., et al. (2000). Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. International Journal of Cancer, 87(2), 261–268.
40.
Shi, Q., Bao, S., Maxwell, J. A., Reese, E. D., Friedman, H. S., Bigner, D. D., et al. (2004). Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. Journal of Biological Chemistry, 279(50), 52200–52209.PubMed
41.
McClung, H. M., Thomas, S. L., Osenkowski, P., Toth, M., Menon, P., Raz, A., et al. (2007). SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neuroscience Letters, 419(2), 172–177.PubMed
42.
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436(7050), 518–524.PubMed
43.
Campo-McKnight, D. A., Sosnoski, D. M., Koblinski, J. E., & Gay, C. V. (2006). Roles of osteonectin in the migration of breast cancer cells into bone. Journal of Cellular Biochemistry, 97(2), 288–302.PubMed
44.
Jacob, K., Webber, M., Benayahu, D., & Kleinman, H. K. (1999). Osteonectin promotes prostate cancer cell migration and invasion: Possible mechanism for metastasis to bone. Cancer Research, 59(17), 4453–4457.PubMed
45.
De, S., Chen, J., Narizhneva, N. V., Heston, W., Brainard, J., Sage, E. H., et al. (2003). molecular pathway for cancer metastasis to bone. Journal of Biological Chemistry, 278(40), 39044–39050.PubMed
46.
Chen, N., Ye, X. C., Chu, K., Navone, N. M., Sage, E. H., Yu-Lee, L. Y., et al. (2007). A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Research, 67(14), 6544–6548.PubMed
47.
Koblinski, J. E., Kaplan-Singer, B. R., VanOsdol, S. J., Wu, M., Engbring, J. A., Wang, S., et al. (2005). Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Research, 65(16), 7370–7377.PubMed
48.
Finocchiaro, G., Mancuso, F. M., Cittaro, D., & Muller, H. (2007). Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME. Nucleic Acids Research, 35(7), 2343–2355.PubMed
49.
Chlenski, A., Liu, S., Crawford, S. E., Volpert, O. V., DeVries, G. H., Evangelista, A., et al. (2002). SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Research, 62(24), 7357–7363.PubMed
50.
Chlenski, A., Liu, S., Baker, L. J., Yang, Q., Tian, Y., Salwen, H. R., et al. (2004). Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Research, 64(20), 7420–7425.PubMed
51.
Said, N., Socha, M. J., Olearczyk, J. J., Elmarakby, A. A., Imig, J. D., & Motamed, K. (2007). Normalization of the ovarian cancer microenvironment by SPARC. Molecular Cancer Research, 5(10), 1015–1030.PubMed
52.
Said, N. A., Najwer, I., Socha, M. J., Fulton, D. J., Mok, S. C., & Motamed, K. (2007). SPARC inhibits LPA-mediated mesothelial–ovarian cancer cell crosstalk. Neoplasia, 9(1), 23–35.PubMed
53.
Yiu, G. K., Chan, W. Y., Ng, S. W., Chan, P. S., Cheung, K. K., Berkowitz, R. S., et al. (2001). SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. American Journal of Pathology, 159(2), 609–622.PubMed
54.
Mok, S. C., Chan, W. Y., Wong, K. K., Muto, M. G., & Berkowitz, R. S. (1996). SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene, 12, 1895–1901.PubMed
55.
Said, N., & Motamed, K. (2005). Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. American Journal of Pathology, 167(6), 1739–1752.PubMed
56.
Brown, T. J., Shaw, P. A., Karp, X., Huynh, M. H., Begley, H., & Ringuette, M. J. (1999). Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecologic Oncology, 75(1), 25–33.PubMed
57.
Tai, I. T., Dai, M., Owen, D. A., & Chen, L. B. (2005). Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. Journal of Clinical Investigation, 115(6), 1492–1502.PubMed
58.
Taghizadeh, F., Tang, M. J., & Tai, I. T. (2007). Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Molecular Cancer Therapeutics, 6(1), 309–317.PubMed
59.
Tang, M. J., & Tai, I. T. (2007). A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. Journal of Biological Chemistry, 282(47), 34457–34467.PubMed
60.
Yang, E., Kang, H. J., Koh, K. H., Rhee, H., Kim, N. K., & Kim, H. (2007). Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. International Journal of Cancer, 121(3), 567–575.
61.
Wiese, A. H., Auer, J., Lassmann, S., Nahrig, J., Rosenberg, R., Hofler, H., et al. (2007). Identification of gene signatures for invasive colorectal tumor cells. Cancer Detection and Prevention, 31(4), 282–295.PubMed
62.
Nguyen, Q. D., De Wever, O., Bruyneel, E., Hendrix, A., Xie, W. Z., Lombet, A., et al. (2005). Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho–Rho kinase axis and tumor microenvironment. Oncogene, 24(56), 8240–8251.PubMed
63.
Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., et al. (1995). Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. International Journal of Cancer, 64, 70–75.
64.
Guweidhi, A., Kleeff, J., Adwan, H., Giese, N. A., Wente, M. N., Giese, T., et al. (2005). Osteonectin influences growth and invasion of pancreatic cancer cells. Annals of Surgery, 242(2), 224–234.PubMed
65.
Infante, J. R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A. P., Riall, T. A., et al. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. Journal of Clinical Oncology, 25(3), 319–325.PubMed
66.
Koukourakis, M. I., Giatromanolaki, A., Brekken, R. A., Sivridis, E., Gatter, K. C., Harris, A. L., et al. (2003). Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Research, 63(17), 5376–5380.PubMed
67.
Sato, N., Fukushima, N., Maehara, N., Matsubayashi, H., Koopmann, J., Su, G. H., et al. (2003). SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions. Oncogene, 22(32), 5021–5030.PubMed
68.
López-Haber, C., Gottifredi, V., Llera, A. S., Salvatierra, E., Prada, F., Alonso, L., et al. (2008). SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated. International Journal of Cancer, 122(7), 1465–1475.
69.
Prada, F., Benedetti, L. G., Bravo, A. I., Alvarez, M. J., Carbone, C., & Podhajcer, O. L. (2007). SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. Journal of Investigative Dermatology, 127(11), 2618–2628.PubMed
70.
Brekken, R. A., Puolakkainen, P., Graves, D. C., Workman, G., Lubkin, S. R., & Sage, E. H. (2003). Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. Journal of Clinical Investigation, 111(4), 487–495.PubMed
71.
Sangaletti, S., Stoppacciaro, A., Guiducci, C., Torrisi, M. R., & Colombo, M. P. (2003). Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. Journal of Experimental Medicine, 198(10), 1475–1485.PubMed
72.
Framson, P. E., & Sage, E. H. (2004). SPARC and tumor growth: Where the seed meets the soil? Journal of Cellular Biochemistry, 92(4), 679–690.PubMed
73.
Gooden, M. D., Vernon, R. B., Bassuk, J. A., & Sage, E. H. (1999). Cell cycle-dependent nuclear location of the matricellular protein SPARC: Association with the nuclear matrix. Journal of Cellular Biochemistry, 74(2), 152–167.PubMed
74.
Sodek, J., Zhu, B., Huynh, M. H., Brown, T. J., & Ringuette, M. (2002). Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connective Tissue Research, 43(2–3), 308–319.PubMed
75.
Yan, Q., Weaver, M., Perdue, N., & Sage, E. H. (2005). Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cells. Journal of Cellular Physiology, 203(1), 286–294.PubMed
76.
Sage, E. H., Johnson, C., & Bornstein, P. (1984). Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. Journal of Biological Chemistry, 259, 3993–4007.PubMed
77.
Funk, S. E., & Sage, E. H. (1993). Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. Journal of Cellular Physiology, 154, 53–63.PubMed
78.
Funk, S. E., & Sage, E. H. (1991). The Ca2+-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 88, 2648–2652.PubMed
79.
Kupprion, C., Motamed, K., & Sage, E. H. (1998). SPARC (BM-40, Osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. Journal of Biological Chemistry, 273(45), 29635–29640.PubMed
80.
Lau, C. P., Poon, R. T., Cheung, S. T., Yu, W. C., & Fan, S. T. (2006). SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. Journal of Pathology, 210(4), 459–468.PubMed
81.
Charest, A., Pepin, A., Shetty, R., Cote, C., Voisine, P., Dagenais, F., et al. (2006). Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart, 92(12), 1844–1849.PubMed
82.
Iruela Arispe, M. L., Lane, T. F., Redmond, D., Reilly, M., Bolender, R. P., Kavanagh, T. J., et al. (1995). Expression of SPARC during development of the chicken chorioallantoic membrane: Evidence for regulated proteolysis in vivo. Molecular Biology of the Cell, 6(3), 327–343.PubMed
83.
Lane, T. F., Iruela-Arispe, M. L., Johnson, R. S., & Sage, E. H. (1994). SPARC is a source of copper-binding peptides that stimulate angiogenesis. Journal of Cell Biology, 125, 929–943.PubMed
84.
Sage, E. H., Reed, M., Funk, S. E., Truong, T., Steadele, M., Puolakkainen, P., et al. (2003). Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. Journal of Biological Chemistry, 278(39), 37849–37857.PubMed
85.
Sasaki, T., Miosge, N., & Timpl, R. (1999). Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. Matrix Biology, 18(5), 499–508.PubMed
86.
Kato, Y., Lewalle, J. M., Baba, Y., Tsukuda, M., Sakai, N., Baba, M., et al. (2001). Induction of SPARC by VEGF in human vascular endothelial cells. Biochemical and Biophysical Research Communications, 287(2), 422–426.PubMed
87.
Nozaki, M., Sakurai, E., Raisler, B. J., Baffi, J. Z., Witta, J., Ogura, Y., et al. (2006). Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. Journal of Clinical Investigation, 116(2), 422–429.PubMed
88.
Ferrari, G., Pintucci, G., Seghezzi, G., Hyman, K., Galloway, A. C., & Mignatti, P. (2006). VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 103(46), 17260–17265.PubMed
89.
Choi, M. E., & Ballermann, B. J. (1995). Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. Journal of Biological Chemistry, 270(36), 21144–21150.PubMed
90.
Thiery, J. P. (2002). Epithelial–mesenchymal transitions in tumour progression. Nature Reviews. Cancer, 2(6), 442–454.PubMed
91.
Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., et al. (2000). The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology, 2(2), 76–83.PubMed
92.
De Craene, B., van Roy, F., & Berx, G. (2005). Unraveling signalling cascades for the Snail family of transcription factors. Cellular Signalling, 17(5), 535–547.PubMed
93.
Moreno-Bueno, G., Cubillo, E., Sarrio, D., Peinado, H., Rodriguez-Pinilla, S. M., Villa, S., et al. (2006). Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial–mesenchymal transition. Cancer Research, 66(19), 9543–9556.PubMed
94.
Robert, G., Gaggioli, C., Bailet, O., Chavey, C., Abbe, P., Aberdam, E., et al. (2006). SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Research, 66(15), 7516–7523.PubMed
95.
Alonso, S. R., Tracey, L., Ortiz, P., Perez-Gomez, B., Palacios, J., Pollan, M., et al. (2007). A high-throughput study in melanoma identifies epithelial–mesenchymal transition as a major determinant of metastasis. Cancer Research, 67(7), 3450–3460.PubMed
96.
Bierie, B., & Moses, H. L. (2006). Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nature Reviews. Cancer, 6(7), 506–520.PubMed
97.
Ford, R., Wang, G., Jannati, P., Adler, D., Racanelli, P., Higgins, P. J., et al. (1993). Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: Regulation via a TGF-beta-dependent pathway. Experimental Cell Research, 206(2), 261–275.PubMed
98.
Bassuk, J. A., Pichler, R., Rothmier, J. D., Pippen, J., Gordon, K., Meek, R. L., et al. (2000). Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. Kidney International, 57(1), 117–128.PubMed
99.
Francki, A., Bradshaw, A. D., Bassuk, J. A., Howe, C. C., Couser, W. G., & Sage, E. H. (1999). SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. Journal of Biological Chemistry, 274(45), 32145–32152.PubMed
100.
Reed, M. J., Vernon, R. B., Abrass, I. B., & Sage, E. H. (1994). TGF-b 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. Journal of Cellular Physiology, 158(1), 169–179.PubMed
101.
Shiba, H., Uchida, Y., Kamihagi, K., Sakata, M., Fujita, T., Nakamura, S., et al. (2001). Transforming growth factor-beta1 and basic fibroblast growth factor modulate osteocalcin and osteonectin/SPARC syntheses in vitamin-D-activated pulp cells. Journal of Dental Research, 80(7), 1653–1659.PubMedCrossRef
102.
Wrana, J. L., Overall, C. M., & Sodek, J. (1991). Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. European Journal of Biochemistry, 197, 519–528.PubMed
103.
Pavasant, P., Yongchaitrakul, T., Pattamapun, K., & Arksornnukit, M. (2003). The synergistic effect of TGF-beta and 1,25-dihydroxyvitamin D3 on SPARC synthesis and alkaline phosphatase activity in human pulp fibroblasts. Archives of Oral Biology, 48(10), 717–722.PubMed
104.
Francki, A., McClure, T. D., Brekken, R. A., Motamed, K., Murri, C., Wang, T., et al. (2004). SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. Journal of Cellular Biochemistry, 91(5), 915–925.PubMed
105.
Schiemann, B. J., Neil, J. R., & Schiemann, W. P. (2003). SPARC inhibits epithelial cell proliferation in part through stimulation of the TGF-beta-signaling system. Molecular Biology of the Cell, 14(10), 3977–3988.PubMed
106.
Bradshaw, A. D., Reed, M. J., Carbon, J. G., Pinney, E., Brekken, R. A., & Sage, E. H. (2001). Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. Wound Repair and Regeneration, 9(6), 522–530.PubMed
107.
Peinado, H., Quintanilla, M., & Cano, A. (2003). Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: Mechanisms for epithelial mesenchymal transitions. Journal of Biological Chemistry, 278(23), 21113–21123.PubMed
108.
McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J., Brunton, V. G., & Frame, M. C. (2005). The role of focal-adhesion kinase in cancer—A new therapeutic opportunity. Nature Reviews. Cancer, 5(7), 505–515.PubMed
109.
Shi, Q., Bao, S., Song, L., Wu, Q., Bigner, D. D., Hjelmeland, A. B., et al. (2007). Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene, 26(28), 4084–4094.PubMed
110.
Coussens, L. M., & Werb, Z. (1996). Matrix metalloproteinases and the development of cancer. Chemistry & Biology, 3, 895–904.
111.
Alvarez, M. J., Prada, F., Salvatierra, E., Bravo, A. I., Lutzky, V. P., Carbone, C., et al. (2005). Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Research, 65(12), 5123–5132.PubMed
112.
Savani, R. C., Zhou, Z., Arguiri, E., Wang, S., Vu, D., Howe, C. C., et al. (2000). Bleomycin-induced pulmonary injury in mice deficient in SPARC. AJP—Lung Cellular and Molecular Physiology, 279(4), L743–L750.PubMed
113.
Sangaletti, S., Gioiosa, L., Guiducci, C., Rotta, G., Rescigno, M., Stoppacciaro, A., et al. (2005). Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. Journal of Cell Science, 118(Pt 16), 3685–3694.PubMed
114.
Rempel, S. A., Hawley, R. C., Gutierrez, J. A., Mouzon, E., Bobbitt, K. R., Lemke, N., et al. (2007). Splenic and immune alterations of the Sparc-null mouse accompany a lack of immune response. Genes and Immunity, 8(3), 262–274.PubMed
115.
Vannahme, C., Gosling, S., Paulsson, M., Maurer, P., & Hartmann, U. (2003). Characterization of SMOC-2, a modular extracellular calcium-binding protein. Biochemical Journal, 373(Pt 3), 805–814.PubMed
116.
Rocnik, E. F., Liu, P., Sato, K., Walsh, K., & Vaziri, C. (2006). The novel SPARC family member SMOC-2 potentiates angiogenic growth factor activity. Journal of Biological Chemistry, 281(32), 22855–22864.PubMed
117.
Girard, J.-P., & Springer, T. A. (1995). Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity, 2, 113–123.PubMed
118.
Girard, J.-P., & Springer, T. A. (1996). Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. Journal of Biological Chemistry, 271(8), 4511–4517.PubMed
119.
Nelson, P. S., Plymate, S. R., Wang, K., True, L. D., Ware, J. L., Gan, L., et al. (1998). Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Research, 58(2), 232–236.PubMed
120.
Bendik, I., Schraml, P., & Ludwig, C. U. (1998). Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Research, 58(4), 626–629.PubMed
121.
Claeskens, A., Ongenae, N., Neefs, J. M., Cheyns, P., Kaijen, P., Cools, M., et al. (2000). Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. British Journal of Cancer, 82(6), 1123–1130.PubMed
122.
Esposito, I., Kayed, H., Keleg, S., Giese, T., Sage, E. H., Schirmacher, P., et al. (2007). Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia, 9(1), 8–17.PubMed
123.
Jazaeri, A. A., Awtrey, C. S., Chandramouli, G. V., Chuang, Y. E., Khan, J., Sotiriou, C., et al. (2005). Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clinical Cancer Research, 11(17), 6300–6310.PubMed
124.
Briggs, J., Chamboredon, S., Castellazzi, M., Kerry, J. A., & Bos, T. J. (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene, 21(46), 7077–7091.PubMed
125.
Lopez, M. V., Blanco, P., Viale, D. L., Cafferata, E. G., Carbone, C., Gould, D., et al. (2006). Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth. Molecular Cancer Therapeutics, 5(10), 2503–2511.PubMed
126.
Zajchowski, D. A., Bartholdi, M. F., Gong, Y., Webster, L., Liu, H.-L., Munishkin, A., et al. (2001). Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Research, 61(13), 5168–5178.PubMed
127.
Woelfle, U., Cloos, J., Sauter, G., Riethdorf, L., Janicke, F., van Diest, P., et al. (2003). Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Research, 63(18), 5679–5684.PubMed
128.
Watkins, G., Martin, T. A., Bryce, R., Mansel, R. E., & Jiang, W. G. (2005). Gamma-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells. Prostaglandins, Leukotrienes and Essential Fatty Acids, 72(4), 273–278.
129.
Castronovo, V., & Bellahcene, A. (1998). Evidence that breast cancer associated microcalcifications are mineralized malignant cells. International Journal of Oncology, 12(2), 305–308.PubMed
130.
Porter, D., Lahti-Domenici, J., Keshaviah, A., Bae, Y. K., Argani, P., Marks, J., et al. (2003). Molecular markers in ductal carcinoma in situ of the breast. Molecular Cancer Research, 1(5), 362–375.PubMed
131.
Dairkee, S. H., Ji, Y., Ben, Y., Moore, D. H., Meng, Z., & Jeffrey, S. S. (2004). A molecular ‘signature’ of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics, 5, 47.PubMed
132.
Amatschek, S., Koenig, U., Auer, H., Steinlein, P., Pacher, M., Gruenfelder, A., et al. (2004). Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Research, 64(3), 844–856.PubMed
133.
Jansen, M. P. H. M., Foekens, J. A., van Staveren, I. L., Dirkzwager-Kiel, M. M., Ritstier, K., Look, M. P., et al. (2005). Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. Journal of Clinical Oncology, 23(4), 732–740.PubMed
134.
Sturm, R. A., Satyamoorthy, K., Meier, F., Gardiner, B. B., Smit, D. J., Vaidya, B., et al. (2002). Osteonectin/SPARC induction by ectopic b3 integrin in human radial growth phase primary melanoma cells. Cancer Research, 62, 226–232.PubMed
135.
Kuphal, S., Palm, H. G., Poser, I., & Bosserhoff, A. K. (2005). Snail-regulated genes in malignant melanoma. Melanoma Research, 15(4), 305–313.PubMed
136.
Menon, P. M., Gutierrez, J. A., & Rempel, S. A. (2000). A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: High SPARC secretion correlates with decreased migration on vitronectin. International Journal of Oncology, 17(4), 683–693.PubMed
137.
Huang, H., Colella, S., Kurrer, M., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2000). Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Research, 60(24), 6868–6874.PubMed
138.
Rempel, S. A., Golembieski, W. A., Fisher, J. L., Maile, M., & Nakeff, A. (2001). SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. Journal of Neuro-oncology, 53, 149–160.PubMed
139.
Golembieski, W. A., & Rempel, S. A. (2002). cDNA array analysis of SPARC-modulated changes in glioma gene expression. Journal of Neuro-oncology, 60(3), 213–226.PubMed
140.
Zhou, X., Tan, F. K., Guo, X., Wallis, D., Milewicz, D. M., Xue, S., et al. (2005). Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts. Arthritis and Rheumatism, 52(1), 257–261.PubMed
141.
Cantarella, G., Risuglia, N., Dell’eva, R., Lempereur, L., Albini, A., Pennisi, G., et al. (2006). TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. British Journal of Cancer, 94(10), 1428–1435.PubMed
142.
Kunigal, S., Gondi, C. S., Gujrati, M., Lakka, S. S., Dinh, D. H., Olivero, W. C., et al. (2006). SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. International Journal of Oncology, 29(6), 1349–1357.PubMed
143.
Gagliano, N., Moscheni, C., Torri, C., Magnani, I., Bertelli, A. A., Nowicky, W., et al. (2006). Effect of Ukrain on matrix metalloproteinase-2 and secreted protein acidic and rich in cysteine (SPARC) expression in human glioblastoma cells. Anticancer Drugs, 17(2), 189–194.PubMed
144.
Colin, C., Baeza, N., Bartoli, C., Fina, F., Eudes, N., Nanni, I., et al. (2006). Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene, 25(19), 2818–2826.PubMed
145.
Rempel, S. A., Ge, S., & Gutiérrez, J. A. (1999). SPARC: A potential diagnostic marker of invasive meningiomas. Clinical Cancer Research, 5, 237–241.PubMed
146.
Rich, J. N., Hans, C., Jones, B., Iversen, E. S., McLendon, R. E., Rasheed, B. K., et al. (2005). Gene expression profiling and genetic markers in glioblastoma survival. Cancer Research, 65(10), 4051–4058.PubMed
147.
Volmer, M. W., Radacz, Y., Hahn, S. A., Klein-Scory, S., Stuhler, K., Zapatka, M., et al. (2004). Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a “secretome” analysis. Proteomics, 4(5), 1324–1334.PubMed
148.
Sansom, O. J., Mansergh, F. C., Evans, M. J., Wilkins, J. A., & Clarke, A. R. (2007). Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice. Gut, 56(10), 1410–1414.PubMed
149.
Madoz-Gurpide, J., Lopez-Serra, P., Martinez-Torrecuadrada, J. L., Sanchez, L., Lombardia, L., & Casal, J. I. (2006). Proteomics-based validation of genomic data: Applications in colorectal cancer diagnosis. Molecular & Cellular Proteomics, 5(8), 1471–1483.
150.
Kaiser, S., Park, Y. K., Franklin, J. L., Halberg, R. B., Yu, M., Jessen, W. J., et al. (2007). Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biology, 8, R131.PubMed
151.
Lecrone, V., Li, W., Devoll, R. E., Logothetis, C., & Farach-Carson, M. C. (2000). Calcium signals in prostate cancer cells: Specific activation by bone-matrix proteins. Cell Calcium, 27(1), 35–42.PubMed
152.
Thomas, R., True, L. D., Bassuk, J. A., Lange, P. H., & Vessella, R. L. (2000). Differential expression of osteonectin/SPARC during human prostate cancer progression. Clinical Cancer Research, 6(3), 1140–1149.PubMed
153.
Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 101(3), 811–816.PubMed
154.
Best, C. J., Gillespie, J. W., Yi, Y., Chandramouli, G. V., Perlmutter, M. A., Gathright, Y., et al. (2005). Molecular alterations in primary prostate cancer after androgen ablation therapy. Clinical Cancer Research, 11(19 Pt 1), 6823–6834.PubMed
155.
Kato, Y., Sakai, N., Baba, M., Kaneko, S., Kondo, K., Kubota, Y., et al. (1998). Stimulation of motility of human renal cell carcinoma by SPARC/Osteonectin/BM-40 associated with type IV collagen. Invasion Metastasis, 18(2), 105–114.PubMed
156.
Sakai, N., Baba, M., Nagasima, Y., Kato, Y., Hirai, K., Kondo, K., et al. (2001). SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma. Human Pathology, 32(10), 1064–1070.PubMed
157.
Gieseg, M. A., Cody, T., Man, M. Z., Madore, S. J., Rubin, M. A., & Kaldjian, E. P. (2002). Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC Bioinformatics, 3, 26.PubMed
158.
Luo, A., Kong, J., Hu, G., Liew, C. C., Xiong, M., Wang, X., et al. (2004). Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene, 23(6), 1291–1299.PubMed
159.
Mitas, M., Almeida, J. S., Mikhitarian, K., Gillanders, W. E., Lewin, D. N., Spyropoulos, D. D., et al. (2005). Accurate discrimination of Barrett’s esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clinical Cancer Research, 11(6), 2205–2214.PubMed
160.
Che, Y., Luo, A., Wang, H., Qi, J., Guo, J., & Liu, Z. (2006). The differential expression of SPARC in esophageal squamous cell carcinoma. International Journal of Molecular Medicine, 17(6), 1027–1033.PubMed
161.
Porte, H., Triboulet, J. P., Kotelevets, L., Carrat, F., Prevot, S., Nordlinger, B., et al. (1998). Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: Implications for prognosis. Clinical Cancer Research, 4(6), 1375–1382.PubMed
162.
Yamashita, K., Upadhay, S., Mimori, K., Inoue, H., & Mori, M. (2003). Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer, 97(10), 2412–2419.PubMed
163.
Brabender, J., Marjoram, P., Lord, R. V., Metzger, R., Salonga, D., Vallbohmer, D., et al. (2005). The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett’s esophagus and patients with Barrett’s-associated adenocarcinoma. Cancer Epidemiology, Biomarkers & Prevention, 14(9), 2113–2117.
164.
Siddiq, F., Sarkar, F. H., Wali, A., Pass, H. I., & Lonardo, F. (2004). Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. Lung Cancer, 45(2), 197–205.PubMed
165.
De Vos, J., Thykjaer, T., Tarte, K., Ensslen, M., Raynaud, P., Requirand, G., et al. (2002). Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene, 21(44), 6848–6857.PubMed
166.
Hedvat, C. V., Comenzo, R. L., Teruya-Feldstein, J., Olshen, A. B., Ely, S. A., Osman, K., et al. (2003). Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. British Journal of Haematology, 122(5), 728–744.PubMed
167.
Martinez, N., Camacho, F. I., Algara, P., Rodriguez, A., Dopazo, A., Ruiz-Ballesteros, E., et al. (2003). The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research, 63(23), 8226–8232.PubMed
168.
Aouacheria, A., Navratil, V., Lopez-Perez, R., Gutierrez, N. C., Churkin, A., Barash, D., et al. (2007). In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions. BMC Genomics, 8, 2.PubMed
169.
Bloomston, M., Ellison, E. C., Muscarella, P., Al-Saif, O., Martin, E. W., Melvin, W. S., et al. (2007). Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer. Annals of Surgical Oncology, 14(1), 211–217.PubMed
170.
Prenzel, K. L., Warnecke-Eberz, U., Xi, H., Brabender, J., Baldus, S. E., Bollschweiler, E., et al. (2006). Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncology Reports, 15(5), 1397–1401.PubMed
171.
Le Bail, B., Faouzi, S., Boussarie, L., Guirouilh, J., Blanc, J. F., Carles, J., et al. (1999). Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. Journal of Pathology, 189(1), 46–52.PubMed
172.
Goldenberg, D., Ayesh, S., Schneider, T., Pappo, O., Jurim, O., Eid, A., et al. (2002). Analysis of differentially expressed genes in hepatocellular carcinoma using cDNA arrays. Molecular Carcinogenesis, 33, 113–124.PubMed
173.
Maeng, H. Y., Song, S. B., Choi, D. K., Kim, K. E., Jeong, H. Y., Sakaki, Y., et al. (2002). Osteonectin-expressing cells in human stomach cancer and their possible clinical significance. Cancer Letters, 184(1), 117–121.PubMed
174.
Inoue, H., Matsuyama, A., Mimori, K., Ueo, H., & Mori, M. (2002). Prognostic score of gastric cancer determined by cDNA microarray. Clinical Cancer Research, 8(11), 3475–3479.PubMed
175.
Wang, C. S., Lin, K. H., Chen, S. L., Chan, Y. F., & Hsueh, S. (2004). Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance. British Journal of Cancer, 91(11), 1924–1930.PubMed
176.
Paley, P. J., Goff, B. A., Gown, A. M., Greer, B. E., & Sage, E. H. (2000). Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecologic Oncology, 78(3 Pt 1), 336–341.PubMed
177.
Nimphius, W., Moll, R., Olbert, P., Ramaswamy, A., & Barth, P. J. (2007). CD34+ fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder. Virchows Archiv, 450(2), 179–185.PubMed
178.
Yamanaka, M., Kanda, K., Li, N.-C., Fukumori, T., Oka, N., Kanayama, H.-O., et al. (2001). Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. Journal of Urology, 166, 2495–2499.PubMed
179.
Chen, Y., Miller, C., Mosher, R., Zhao, X., Deeds, J., Morrissey, M., et al. (2003). Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Research, 63(8), 1927–1935.PubMed
180.
Sova, P., Feng, Q., Geiss, G., Wood, T., Strauss, R., Rudolf, V., et al. (2006). Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiology, Biomarkers & Prevention, 15(1), 114–123.
181.
Rodriguez-Jimenez, F. J., Caldes, T., Iniesta, P., Vidart, J. A., Garcia-Asenjo, J. L., & Benito, M. (2007). Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma. Oncology Reports, 17(6), 1301–1307.PubMed
182.
Fanburg-Smith, J. C., Bratthauer, G. L., & Miettinen, M. (1999). Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: A study of 28 cases. Human Pathology, 30(1), 32–38.PubMed
183.
Dalla-Torre, C. A., Yoshimoto, M., Lee, C. H., Joshua, A. M., de Toledo, S. R., Petrilli, A. S., et al. (2006). Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer, 6(1), 237.PubMed
184.
Takano, T., Hasegawa, Y., Miyauchi, A., Matsuzuka, F., Yoshida, H., Kuma, K., et al. (2002). Quantitative analysis of osteonectin mRNA in thyroid carcinomas. Endocrine Journal, 49(4), 511–516.PubMed
185.
Chin, D., Boyle, G. M., Williams, R. M., Ferguson, K., Pandeya, N., Pedley, J., et al. (2005). Novel markers for poor prognosis in head and neck cancer. International Journal of Cancer, 113(5), 789–797.
186.
Aycock, R. L., Bradshaw, A. C., Sage, E. H., & Starcher, B. (2004). Development of UV-induced squamous cell carcinomas is suppressed in the absence of SPARC. Journal of Investigative Dermatology, 123(3), 592–599.PubMed
187.
Said, N., Najwer, I., & Motamed, K. (2007). Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. American Journal of Pathology, 170(3), 1054–1063.PubMed
188.
Cody, N. A., Ouellet, V., Manderson, E. N., Quinn, M. C., Filali-Mouhim, A., Tellis, P., et al. (2007). Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene, 26(4), 618–632.PubMed
189.
Dhanesuan, N., Sharp, J. A., Blick, T., Price, J. T., & Thompson, E. W. (2002). Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Research and Treatment, 75(1), 73–85.PubMed
190.
Bergamaschi, A., Tagliabue, E., Sorlie, T., Naume, B., Triulzi, T., Orlandi, R., et al. (2007). Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. Journal of Pathology, 214(3), 357–367.
191.
Tang, H., Wang, J., Bai, F., Hong, L., Liang, J., Gao, J., et al. (2007). Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochemistry and Cell Biology, 85(1), 103–110.PubMed
192.
Chlenski, A., Liu, S., Guerrero, L. J., Yang, Q., Tian, Y., Salwen, H. R., et al. (2006). SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. International Journal of Cancer, 118(2), 310–316.
193.
Chlenski, A., Guerrero, L. J., Yang, Q., Tian, Y., Peddinti, R., Salwen, H. R., et al. (2007). SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene, 26(31), 4513–4522.PubMed
194.
Puolakkainen, P., Bradshaw, A. D., Kyriakides, T. R., Reed, M., Brekken, R., Wight, T., et al. (2003). Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. American Journal of Pathology, 162(2), 627–635.PubMed
195.
DiMartino, J. F., Lacayo, N. J., Varadi, M., Li, L., Saraiya, C., Ravindranath, Y., et al. (2006). Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia, 20(3), 426–432.PubMed
Metadata
Title
The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
Authors
Osvaldo L. Podhajcer
Lorena Gabriela Benedetti
Maria Romina Girotti
Federico Prada
Edgardo Salvatierra
Andrea S. Llera
Publication date
01-12-2008
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9146-7

Other articles of this Issue 4/2008

Cancer and Metastasis Reviews 4/2008 Go to the issue

OriginalPaper

Imaging of tumor glucose utilization with positron emission tomography

NON-THEMATIC REVIEW

Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents

Acknowledgments

Biography - Anthony F. Shields, M.D., Ph.D.

OriginalPaper

Non-invasive assessment of tumor neovasculature: techniques and clinical applications

OriginalPaper

Imaging of integrin αvβ3 expression

OriginalPaper

Molecular imaging of epidermal growth factor receptor expression–activity at the kinase level in tumors with positron emission tomography
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits